Effects of kombucha on overweight and obese individuals

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the impact of kombucha, a fermented beverage, on individuals with overweight and class 1 obesity. Participants aged 18 to 60 will be randomly assigned to receive either live kombucha, pasteurized kombucha, or sparkling water for four weeks. The study aims to assess metabolic parameters such as glucose and insulin levels, lipid profiles, gut microbiota composition, and liver function. By comparing the effects of live versus pasteurized kombucha, the research seeks to understand the potential health benefits of this beverage.

Why it matters

Who can join: the full rules

Inclusion Criteria:

Individuals with a Body Mass Index (BMI) between 25 kg/m² and 34.9 kg/m², of both biological sexes, aged between 18 and 60 years, available to comply with the study protocol (described in this document) and sign informed consent.

Exclusion Criteria:

Volunteers will be excluded from the study if they present one or more of the following conditions:

1. Subjects with sensitivity to kombucha;
2. Consumption of kombucha, kefir, kimchi, cheese, raw vinegar, sauerkraut, kvass, and other fermented products during the study and in the 3 weeks before the study.
3. Use of antibiotics in the 6 months prior to the start of the study;
4. Use of pro/prebiotics or fibers as dietary supplements or any food/molecule that modifies intestinal transit time 6 weeks before recruitment; use of laxatives 6 weeks before recruitment;
5. Specific dietary regimen (e.g., vegan); specific dietary treatment (e.g., high protein);
6. Excessive consumption of substances and alcohol; smokers;
7. Diagnosis of gastrointestinal disorders, hormonal or thyroid diseases, autoimmune diseases, and/or chronic use of corticosteroids; psychiatric disease; Type 1 or 2 diabetes;
8. Use of proton pump inhibitors; antidiabetic drugs or insulin and statins;
9. Subjects with insulin sensitivity;
10. Pregnant or lactating women;
11. Subjects with tooth sensitivity
12. Participation in another clinical trial in the last 3 months.

Where it's running

• Centro de Apoio Tecnológico Agro Alimentar (CATAA)
  Castelo Branco, Castelo Branco District, Portugal Recruiting
• Centro de Apoio Tecnológico Agro Alimentar (CATAA) (facilities temporarily provided by the Affidea clinical analysis center)
  Covilha, Portugal Recruiting

Study contacts

• Principal investigator: Brandão, PhD — Cataa
• Study coordinator: Inês Brandão, PhD
• Email: inesbrandao@cataa.pt
• Phone: +351926777221

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• IBI3046 in Overweight or Obesity

  This study tests how safe and tolerable IBI3046 is in adults with overweight or obesity in China.

  Recruiting Phase 1 Innovent Biologics (Suzhou) Co. Ltd. · Beijing, Beijing Municipality · NCT07809945

• Sleep behavioral program for adolescents with overweight or obesity

  This trial will test whether adding a sleep-focused behavioral program to usual weight treatment helps teens (13–17) with overweight or obesity who have poor sleep improve body composition and health markers.

  Recruiting University of Beira Interior · Covilha and 1 other locations · NCT07255274

• Robotic versus laparoscopic conversion to RYGB for revision bariatric surgery

  We will see if robotic surgery or laparoscopy leads to fewer postoperative complications for people having revision bariatric surgery converted to RYGB.

  Recruiting GCS Ramsay Santé pour l'Enseignement et la Recherche · Lyon and 1 other locations · NCT07180316

• Bone health, vitamin D, weight, and fractures in children

  See if blood markers (alkaline phosphatase, calcium, PTH, vitamin D), body weight, and calcium intake are linked to fractures in children aged 3–15 after low-energy trauma.

  Recruiting at 2 sites Paracelsus Medical University · Brixen, Bolzano and 1 other locations · NCT07143552

• Efsubaglutide alfa for adults with overweight or obesity (SPARKLE)

  This trial will test whether efsubaglutide alfa injections given weekly or every few weeks help adults with overweight or obesity lose weight safely.

  Recruiting at 5 sites Phase 2 Shanghai Yinnuo Pharmaceutical Technology Co., Ltd. · Brookvale and 4 other locations · NCT07114419

• Cardiovascular health in children and young adults with chronic conditions

  This project will see if children and young adults (ages 6-25) with chronic health conditions show early signs of aging in large and small blood vessels using noninvasive imaging and clinical tests.

  Recruiting Semmelweis University · Budapest and 2 other locations · NCT07086989

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.